About NUCLEIS
NUCLEIS is a company based in Liege (Belgium) founded in 2017 was acquired by Curium in April 2025. The company has 13 employees as of December 31, 2021. NUCLEIS operates in a competitive market with competitors including Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
- Headquarter Liege, Belgium
- Employees 13 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nucleis
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
13
as on Dec 31, 2021
-
Acquired by
Curium
(Apr 10, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NUCLEIS
Detailed funding history for NUCLEIS
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in NUCLEIS
NUCLEIS has secured backing from 1 investor. Prominent investors backing the company include Curium Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Curium Pharma is recognized as a leader in radiopharmaceuticals.
|
Locked | Locked | Locked |
Investor details for NUCLEIS
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NUCLEIS
Investment portfolio details for NUCLEIS
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NUCLEIS
Detailed financials for NUCLEIS
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nucleis Comparisons
Peer comparison for NUCLEIS
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NUCLEIS
NUCLEIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of antibody discovery, cell line development, and bio analytics services
|
|
| Locked | Locked | Locked |
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry
|
|
| Locked | Locked | Locked |
Provider of contract research and manufacturing services for both small molecules and biologics
|
|
| Locked | Locked | Locked |
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate
|
|
| Locked | Locked | Locked |
Developer of biosimilars, vaccines and natural products
|
|
| Locked | Locked | Locked |
Provides enabling tools and services in the life sciences research and bio-production industries
|
Detailed competitors of NUCLEIS
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nucleis
Complete news archive for NUCLEIS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NUCLEIS
NUCLEIS was founded in 2017.
NUCLEIS is headquartered in Liege, Belgium. It is registered at Liege, Liege, Belgium.
Fabrice Giacomelli is the current CEO of NUCLEIS.
As of Dec 31, 2021, the latest employee count at NUCLEIS is 13.
NUCLEIS was established in 2017 in Liege, Belgium, where operations are centered on contract manufacturing within the nuclear medicine sector. PET radio-pharmaceutical drugs are produced for positron emission tomography applications in medical diagnostics. Services encompass formulation, synthesis, and quality control processes tailored to client specifications. The focus remains on regulatory compliance and supply chain efficiency for pharmaceutical partners across Europe.
NUCLEIS's top competitors include Abzena, Syngene and Grand River Aseptic Manufacturing.
NUCLEIS has 1 investor. Key investors include Curium Pharma.